Nyxoah S.A. (NYXH)

Market Cap	303.79M
Revenue (ttm)	5.67M
Net Income (ttm)	-59.09M
Shares Out	37.39M
EPS (ttm)	-1.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,806
Open	7.98
Previous Close	8.00
Day's Range	7.85 - 8.24
52-Week Range	4.00 - 20.00
Beta	0.55
Analysts	Strong Buy
Price Target	17.00 (+112.24%)
Earnings Date	Nov 6, 2024

About NYXH

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Jul 2, 2021
• Employees: 147
• Stock Exchange: NASDAQ
• Ticker Symbol: NYXH
• Website: https://www.nyxoah.com

Financial Performance

In 2023, Nyxoah's revenue was 4.35 million, an increase of 40.99% compared to the previous year's 3.08 million. Losses were -43.21 million, 38.4% more than in 2022.

Financial numbers in EUR

Analyst Forecast

According to 5 analysts, the average rating for NYXH stock is "Strong Buy." The 12-month stock price forecast is $17.0, which is an increase of 112.24% from the latest price.

Price Target

$17.0

(112.24% upside)

Analyst Consensus: Strong Buy